PROCEPT BioRobotics Corp (PRCT) stock
Close on Nov 11, 2026Market cap $1.34BP/E –Yield –
PROCEPT BioRobotics Corp grew revenue 17.5% to $352.30M over the twelve months to Sep 30, 2026. Free cash flow was -$85.07M. At the latest close the market valued the company at $1.34B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.34B
- P/E ratio
- –
- Price to sales
- 3.79
- Price to book
- 4.06
- Dividend yield
- –
- Free cash flow yield
- -6.36%
Fundamentals
- Revenue
- $352.30M
- Net income
- -$114.86M
- EPS, diluted
- -$2.02
- Free cash flow
- -$85.07M
- Book value per share
- $5.74
- Diluted shares
- 57M
Trading
- Next earnings
- Feb 24, 2027 (estimated, after the close)
- Previous close
- $23.05
- Open
- $22.97
- Day's range
- $22.55 – $23.36
- Volume
- 970,686
- Average volume (20 days)
- 1,293,731
- Index membership
- Russell 2000 (since Dec 2021), Russell 3000 (since Feb 2022)
- Beta (5 years)
- 1.31
- 52-week range
- $16.66 – $38.11
- RSI (14 days)
- 67.4
- Volatility (1 year)
- 65.8%
- Relative volume
- 0.68×
- WACC
- 11.2%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | PRCT | S&P 500 | Difference | PRCT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +26.8% | -2.4% | +29.3 pts | ||
| 3 months | +2.0% | -1.2% | +3.1 pts | ||
| Year to date | -25.8% | +12.3% | −38.1 pts | ||
| 1 year | -25.5% | +12.4% | −38.0 pts | ||
| 3 years | -24.7% | +78.8% | −103.5 pts | -9.0% | +21.4% |
| 5 years | -44.3% | +75.2% | −119.5 pts | -11.0% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases PROCEPT BioRobotics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Update
- Results
- Results
About PROCEPT BioRobotics
Surgical & Medical Instruments & Apparatus
The company develops, manufactures, and sells image-guided surgical robotic systems for minimally invasive urology, focusing on treating benign prostatic hyperplasia. Its primary products are the AquaBeam Robotic System and the HYDROS Robotic System. Each system utilizes single-use disposable handpieces to deliver Aquablation therapy, combining ultrasound imaging, robotic automation, and heat-free waterjet ablation to remove prostate tissue. The company primarily sells its products to hospitals, as well as to ambulatory surgery centers, distribution partners, and leasing companies.
Company profile, executives and historyPROCEPT BioRobotics stock: common questions
What is PROCEPT BioRobotics's stock price?
PRCT closed at $23.34 on Nov 11, 2026, up 1.26% on the day. Over the past 52 weeks it traded between $16.66 and $38.11.
What is PROCEPT BioRobotics's market cap?
PROCEPT BioRobotics was worth $1.34B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is PRCT's P/E ratio?
PROCEPT BioRobotics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.02), so it has no meaningful P/E ratio.
How much revenue does PROCEPT BioRobotics make?
PROCEPT BioRobotics reported revenue of $352.30M for the twelve months to Sep 30, 2026, up 17.5% from a year earlier.
Does PROCEPT BioRobotics pay a dividend?
No. PROCEPT BioRobotics has not paid a cash dividend over the last twelve months.
When does PROCEPT BioRobotics report earnings next?
PROCEPT BioRobotics is expected to report Q4 FY2026 results on Feb 24, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has PRCT stock performed over the past year?
Including dividends, PRCT returned -25.5% over the past year, against +12.4% for the S&P 500.
How many PRCT shares are sold short?
8M shares were sold short at the latest FINRA report, 14.41% of the float, or 9.0 days of average trading volume.
Who are PROCEPT BioRobotics's competitors?
Companies most similar to PROCEPT BioRobotics by business, industry and size include ARAY, ANGO, SKIN, MDXG, LMAT.
See a number that looks wrong?